February 10, 2012 -Parsippany, NJ, based Watson Pharmaceuticals has announced that it has received U.S. Food and Drug Administration (FDA) approval for the first generic version of the extended release opioid analgesic Kadian (morphine sulfate ER). This Schedule II controlled-substance drug is indicated for the management of constant, moderate to severe pain for an extended period of time. Watson has already begun shipping the new product which is available in strengths of 20, 30, 50, 60, 80 and 100mg capsules.
Extended release morphine sulfate is not meant to be used as needed and only in the treatment of chronic pain. This medication should not be crushed or chewed; patients who experience difficulty swallowing can open the capsule and sprinkle its contents onto applesauce although care must be taken not to chew or crush the contents. As with all opioid analgesics, there is a risk of abuse, overuse and side effects such as sedation and respiratory depression.
For more information, please refer to the full prescribing information: http://www.watson.com/products/product-database-detail.asp